<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Papadima, Artemisia</style></author><author><style face="normal" font="default" size="100%">Gourgiotis, Stavros</style></author><author><style face="normal" font="default" size="100%">Lagoudianakis, Emmanuel</style></author><author><style face="normal" font="default" size="100%">Pappas, Apostolos</style></author><author><style face="normal" font="default" size="100%">Seretis, Charalampos</style></author><author><style face="normal" font="default" size="100%">Antonakis, Pantelis T</style></author><author><style face="normal" font="default" size="100%">Markogiannakis, Haridimos</style></author><author><style face="normal" font="default" size="100%">Makri, Ira</style></author><author><style face="normal" font="default" size="100%">Manouras, Andreas</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Granisetron versus tropisetron in the prevention of postoperative nausea and vomiting after total thyroidectomy.</style></title><secondary-title><style face="normal" font="default" size="100%">Saudi J Anaesth</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Saudi J Anaesth</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013 Jan</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">7</style></volume><pages><style face="normal" font="default" size="100%">68-74</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">BACKGROUND: Postoperative nausea and vomiting (PONV) are frequently encountered after thyroidectomy. For PONV prevention, selective serotonin 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are considered one of the first-line therapy. We report on the efficiency of granisetron and tropisetron, with that of placebo on the prevention of PONV in patients undergoing total thyroidectomy.

METHODS: One hundred twenty-seven patients were divided into three groups and randomized to receive intravenously, prior to induction of anesthesia, tropisetron 5 mg, or granisetron 3 mg, or normal saline. All patients received additionally 0.625 mg droperidol. All episodes of postoperative PONV during the first 24 h after surgery were evaluated.

RESULTS: Nausea visual analogue scale (VAS) score was lower in tropisetron and granisetron groups than the control group at all measurements (P&lt;0.01) except for the 8-h measurement for tropisetron (P=0.075). Moreover, granisetron performed better than tropisetron (P&lt;0.011 at 4 h and P&lt;0.01 at all other points of time) apart from the 2-h measurement. Vomiting occurred in 22.2%, 27.5%, and 37.5% in granisetron, tropisetron, and control groups, respectively (P=0.43).

CONCLUSIONS: The combination of the 5-HT3 antagonists with droperidol given before induction of anesthesia is well tolerated and superior to droperidol alone in preventing nausea but not vomiting after total thyroidectomy.</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/23717236?dopt=Abstract</style></custom1></record></records></xml>